

VERMILLION, INC. CORPORATE FACT SHEET

CORPORATE OVERVIEW

Vermillion, Inc. (VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion's tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Management concentrates its development of novel diagnostic tests in the fields of oncology, hematology, cardiology and women's health, with the initial focus on ovarian cancer. The Company also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with leading academic and research institutions. Vermillion's corporate offices are located in Austin, Texas.

PRODUCT PIPELINE

OVARIAN CANCER

The Company's ovarian cancer program is directed at developing and commercializing novel high-value diagnostic tests that ultimately could lead to better patient outcomes through appropriate triage, earlier diagnosis, and optimal therapeutic selection.

OVA1™

On March 9, 2010, Vermillion launched OVA1™, the first blood test that is cleared by the U.S. Food & Drug Administration (FDA) for the evaluation of an adnexal mass prior to a planned surgery. OVA1 utilizes a panel of five biomarkers to help identify women with cancer so they can be referred directly to a gynecologic oncologist for their initial surgery, which may improve survival from cancer and reduce the number of second surgeries.

Results from the pivotal study were presented at the 2010 Annual Meeting of the Society of Gynecologic Oncologists (SGO) in San Francisco, CA. OVA1 is available nationally through Quest Diagnostics, Inc. and is covered by Highmark Medicare Services.

Ovarian Cancer High-Risk Triage Test

More than 10 million women are considered to be at high risk for ovarian cancer based on several risk factors, including family history. Vermillion is applying its biomarker technology capabilities to develop a simple blood test that could be used to triage these patients and identify which of these women should be evaluated further for the possibility of having ovarian cancer.

Ovarian Cancer Prognosis Test

Vermillion is developing a blood test to help predict prognosis of ovarian cancer, which may help patients and physicians make more informed treatment decisions. A study presented at the European Society of Gynecologic Oncology meeting in October 2007 found that Vermillion's biomarker panel could accurately and with statistical significance predict women with ovarian cancer who had good prognosis from those who did not.

RECENT CORPORATE HIGHLIGHTS

Corporate Developments:

- Private placement for \$43MM in gross proceeds completed on January 7, 2010
- Plan of Reorganization approved on January 22, 2010
- Appointment of Sandra A. Gardiner as Vice President and Chief Financial Officer
- Launch of OVA1™ ovarian cancer tumor triage test
- The Company's common stock is listed on The NASDAQ Global Market

Ovarian Cancer Program:

- EU Patent Office issues decision to grant patent for "Use of Biomarkers for Detecting Ovarian Cancer"
- Highmark Medicare Services provides favorable medicare decision

Peripheral Artery Disease Program:

- September 2008 – Vermillion and Stanford Scientists receive "Best Clinical Research Award" from the PAD Coalition
- August 2008 - Results of data in support of Vermillion's PAD Disease Test Program published in Vascular Medicine

KEY INFORMATION

- NASDAQ: VRML
- 10.3 million common shares outstanding as of 06/30/10
- 23 employees as of 07/31/10

**Vermillion, Inc.,
12117 Bee Caves Road
Suite 100
Austin, TX 78738
Tel: 512 519 0400
Fax: 512 439 6980**

CARDIOVASCULAR DISEASE

Peripheral Artery Disease (PAD) Blood Test

In collaboration with researchers at Stanford University, Vermillion is developing a novel blood test to stratify an individual's risk of developing PAD, a serious disease estimated to affect up to 12 million Americans.

The test, now named VASCLIR™, has been evaluated in four studies comprising almost 1,000 patients. It simultaneously evaluates various biomarkers for PAD and creates an index score. Vermillion studies have shown that patients with a high index score are seven times more likely to have PAD than patients with a low index score.

In late 2007, Vermillion completed a 540-patient clinical study analyzing the ability of its multi-marker panel to stratify individuals into high and low risk groups for PAD. These results were published in *Vascular Medicine* in August of 2008.

The Company has also established a clinical steering committee to guide and provide advice on additional studies to support registration of VASCLIR with the FDA and to further potential market adoption.

BLOOD DISORDERS

Thrombotic Thrombocytopenic Purpura (TTP) Test

In conjunction with The Ohio State University (OSU) Research Foundation, Vermillion developed a test for the diagnosis and clinical evaluation of TTP, a devastating blood disorder that causes abnormal clotting and carries the risk of neurologic, renal and cardiac dysfunction and even death. The test utilizes mass spectrometry to help physicians make the correct diagnosis, initiate timely treatment, evaluate response to therapy and predict the risk of recurrence in patients with TTP. Vermillion currently licenses the TTP assay to OSU for availability as a laboratory developed test.

STRATEGIC PARTNERSHIPS

The Company and Quest Diagnostics entered into a strategic alliance to develop and commercialize its proteomics-based diagnostics tests.

Vermillion also has collaborations with leading academic and research institutions throughout the world, including the Johns Hopkins University School of Medicine, Stanford University, Rigshospitalet (Copenhagen), and the University of Kentucky.

MANAGEMENT TEAM

Gail S. Page
Chairperson and Chief Executive Officer

Eric T. Fung, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer

Sandra A. Gardiner
Vice President and Chief Financial Officer

John H. Tran
Vice President, Finance and Chief Accounting Officer

William B. Creech
Vice President, Sales and Marketing

BOARD OF DIRECTORS

Gail S. Page
Chairperson and Chief Executive Officer

James S. Burns
President and Chief Executive Officer, AssureRX

John F. Hamilton
Former Vice President and Chief Financial Officer, Depomed, Inc.

Peter S. Roddy
Vice President and Chief Financial Officer, Pain Therapeutics, Inc.

Carl Severinghaus
President, Tecan Americas

William C. Wallen, Ph.D.
Former Chief Scientific Officer and Senior Vice President, Research and Development, IDEXX Laboratories

SCIENTIFIC ADVISORY BOARD

Eric T. Fung, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer

Robert C. Bast, Jr., M.D.
University of Texas M.D. Anderson Cancer Center

Walter Carney, Ph.D.
Head of Oncogene Sciences

Daniel W. Chan, Ph.D., DABCC, FACR
Johns Hopkins University School of Medicine

John P. Cooke, MD., PhD.
Stanford University School of Medicine

Gordon Whiteley, PhD.
National Institutes of Health